为协和、同济供医疗器械年入2亿，浙大博士负债900万带百瑞吉冲IPO

Core Viewpoint - Changzhou Baijiji Bio-Pharmaceutical Co., Ltd. (Baijiji) is focusing on the development of postoperative adhesion prevention products, primarily using sodium hyaluronate, while also expanding into functional skincare products, which have not yet achieved profitability despite significant marketing investments [1][10][12]. Group 1: Business Overview - Baijiji's core business is in the field of adhesion prevention medical devices, which are crucial for gynecological surgeries, helping to reduce complications and healthcare costs [2][25]. - The company's main product, cross-linked sodium hyaluronate gel for the uterine cavity, generated revenues of 113 million yuan, 130 million yuan, 151 million yuan, and 85 million yuan from 2022 to the first half of 2025, accounting for approximately 60% of its main business revenue [2][26]. - Baijiji's products are approved for use in around 2,100 hospitals in China, including approximately 600 top-tier hospitals [9][31]. Group 2: Financial Performance - The company reported revenues of 1.51 billion yuan, 1.98 billion yuan, 2.31 billion yuan, and 1.41 billion yuan from 2022 to the first half of 2025, with net profits of 31 million yuan, 50 million yuan, 52 million yuan, and 41 million yuan respectively [17]. - The gross profit margin for the main business remained high, averaging around 82% over the same period [10][33]. Group 3: Marketing and Expansion Efforts - Baijiji has invested over 100 million yuan in online marketing services over three and a half years to promote its functional skincare line, which has yet to turn a profit, incurring losses exceeding 37 million yuan [12][15][36]. - The functional skincare products, under the "VITREGEN" brand, have seen increasing sales, with revenues of 27.22 million yuan, 44.09 million yuan, 52.93 million yuan, and 39.61 million yuan from 2022 to the first half of 2025, representing a growing share of the company's total revenue [12][35]. Group 4: Market Potential and Challenges - The market for postoperative adhesion prevention products is relatively limited, with a total market size of approximately 3.945 billion yuan in 2023 for uterine, abdominal, and nasal cavity applications [9][32]. - Baijiji's reliance on its main product poses risks if market growth or product penetration does not meet expectations, potentially impacting revenue and profitability [9][33].